Illumina Acquisition Sparks Innovation: ABclonal Launches ABcellar High-Throughput Single-Cell Platform to Empower Scientific Breakthroughs
Illumina
Diagnostic Product Developer
Fluent BioSciences
Single-cell RNA Kit Developer
On July 9, 2024, Illumina, the global leader in gene sequencing instruments, announced the acquisition of Fluent BioSciences with its own cash, becoming the focus in the single-cell sequencing field.
ABclonal, leveraging its years of experience in molecular enzyme raw materials and NGS product development, seizes the latest trends in the single-cell sequencing field.Launch ABcellar High-Throughput Single-Cell Library Construction Platform`, providing researchers with more efficient and precise single-cell research tools.`
ABcellar High-Throughput Single-Cell Library Construction PlatformDeveloped independently by ABclonal, applicable in multiple fields such as oncology, immunology, embryonic development, and prenatal genetic diagnosis, including the ABcellar Single-cell Library Construction System, ABcellar High-throughput Single-cell Transcriptome Library Preparation Kit, and ABcellar Analysis Software.This platform, based on microfluidics and gel-encoded microsphere technology, completes the capture, labeling, library construction, and data analysis of tens of thousands of individual cells in one run.
Figure 1. ABcellar High-Throughput Single-Cell Library Construction Platform
Figure 2. ABcellar Compatible with Multiple Sample Types
Figure 3. ABcellar Cell Populations Show High Consistency with 10X (Human, PBMC)
High Quality and Efficiency:Capable of capturing 40,000 to 200,000 cells in a single run, with a cell capture rate of up to 60% and high sensitivity for genetic testing.
Flexible operation:1-4 channels, with flexible selection of sample numbers and cell quantities.
Convenient and Fast:Cell isolation and demulsification without pipetting, simple and reducing sample loss.
Stable Compatibility:The multiple rate is less than 6%, and the library is compatible with various mainstream sequencing platforms currently available.
An integrated solution, including a complete research process, simplifies operations.
Integrated multifunctional modules, including cell capture, labeling, library construction, and data analysis.
Provide professional technical support and solve problems in the experiment.
Personalized guidance to improve user skill levels.
Independently developed to ensure the quality and stability of the product.
Continuously optimize product performance and process flow to improve economic efficiency.
Scan the code to learn more and participate in the event. Join us now!
Together, let's embrace the new era of single-cell sequencing!
#ABclonal #ABcellar #Single-cell Sequencing #Gene Sequencing #Scientific Innovation
END
ABclonal
Company Profile
ABclonal Technology Co., Ltd. was founded in 2011 as a provider of life science solutions, aiming to offer comprehensive solutions, including antibodies, enzymes, NGS products, and protein products, to more researchers, IVD companies, and new technology development enterprises.
ABclonal currently has the Boston Antibody and Protein Research and Development Center, the Shanghai Diagnostic and Scientific Research Molecular Enzyme Product R&D Base, and the Wuhan Guanggu Diagnostic and Scientific Research Immunology Product Production and R&D Base in China. After years of dedication and development, ABclonal has established two major technological platforms: immunology and molecular enzymes. It integrates the research, development, and production of novel molecular enzymes, comprehensive NGS library preparation solutions for all applications, new platform monoclonal antibodies, and high-activity protein products. ABclonal is committed to becoming a core enterprise in industrial scientific research transformation, providing life science researchers and application enterprises with a full range of reliable technical solutions.
